Michael A. Carducci

Also affiliated with Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyNursing

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 55 papers. Top paper: “Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study”.

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00211-0

N/A

1.9DataRank · unranked

86 citations

Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole +40 more

Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial

The Prostate(2021)10.1002/pros.24110

N/A

1.7DataRank · unranked

71 citations

Karim Boudadi, Wei Fu, Hao Wang, Rana Sullivan, Alice Jordan +12 more

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Nature Communications(2024)10.1038/s41467-023-44514-2

N/A

1.3DataRank · unranked

49 citations

Mary‐Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi +15 more

Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy

European Journal of Cancer(2020)10.1016/j.ejca.2020.11.043

N/A

1.2DataRank · unranked

47 citations

Hao Wang, Su J. Lim ScM, Irina Rifkind, Nduku Ngomba, John T. Isaacs +10 more

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer(2020)10.1186/s12885-020-07000-2

N/A

1.1DataRank · unranked

32 citations

Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan +26 more

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

Journal of Clinical Oncology(2024)10.1200/jco.23.01544

N/A

0.930DataRank · unranked

19 citations

Se Eun Kim, Wayne Harris, Sumanta K. Pal, Michael R. Pins, Jill Kolesar +13 more

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial

Annals of Oncology(2021)10.1016/j.annonc.2021.06.003

N/A

0.654DataRank · unranked

77 citations

Hsin-Chieh Huang, V. Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den +11 more

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial

Cancer Research Communications(2024)10.1158/2767-9764.crc-24-0225

N/A

0.554DataRank · unranked

18 citations

Marianna Zahurak, Adel Mandl, Nicole A. Metri, Aliya Lalji, Elisabeth I. Heath +18 more

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5101

N/A

0.330DataRank · unranked

8 citations

Mäneka Puligandla, Mohamad E. Allaf, David F. McDermott, Charles G. Drake, Sabina Signoretti +15 more

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.06.012

N/A

0.261DataRank · unranked

4 citations

Se Eun Kim, David F. McDermott, Janice P. Dutcher, Mäneka Puligandla, Judith Manola +10 more

Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4541

N/A

0.104DataRank · unranked

1 citations

Se Eun Kim, David F. McDermott, Viraj A. Master, Sabina Signoretti, Mahmut Akgül +13 more

Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e20606

N/A

0.104DataRank · unranked

1 citations

Richard Piekarz, Liza C. Villaruz, John C. Rhee, W. Victoria Lai, Bethany J. Horton +7 more

End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials

Journal of the National Comprehensive Cancer Network(2021)10.6004/jnccn.2020.7646

N/A

0DataRank · unranked

4 citations

Amanda L. Blackford, Arjun Gupta, Kelly Griffiths, Janet Heussner, Michael A. Carducci +1 more

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4596

N/A

0DataRank · unranked

10 citations

Se Eun Kim, Viraj A. Master, David F. McDermott, Sabina Signoretti, David Cella +15 more

EA8185: Phase II study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), ECOG-ACRIN/nrg collaboration.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps500

N/A

0DataRank · unranked

4 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more

Phase III study of local or systemic therapy INtensification DIrected by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps5098

N/A

0DataRank · unranked

3 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

PET-directed local or systemic therapy intensification in prostate cancer patients with post-prostatectomy biochemical recurrence: A trial of the ECOG-ACRIN Cancer Research Group (EA8191).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps267

N/A

0DataRank · unranked

2 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Daniel H. Shevrin +10 more

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)—An ECOG-ACRIN and NRG Collaboration.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4590

N/A

0DataRank · unranked

0 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more

Physicians’ use of plain language during discussions of prostate cancer clinical trials with patients

Patient Education and Counseling(2022)10.1016/j.pec.2022.09.002

N/A

0DataRank · unranked

15 citations

Lauren M. Hamel, Fatmeh Baidoun, Tanina Foster Moore, Ellen Barton, Elisabeth I. Heath +4 more

The international penile advanced cancer trial (InPACT): The first phase III trial for squamous carcinoma of the penis with regional lymph node metastases.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps7

N/A

0DataRank · unranked

15 citations

Steve Nicholson, Philippe E. Spiess, Lance C. Pagliaro, Nick Watkin, Jim Barber +13 more

Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.6089

N/A

0DataRank · unranked

10 citations

R. Michael Tuttle, Ravinder K. Grewal, Eric J. Sherman, Shrujal S. Baxi, Laura Boucai +14 more

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4617

N/A

0DataRank · unranked

4 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps594

N/A

0DataRank · unranked

0 citations

Se Eun Kim, Abhishek A. Solanki, David T. Miyamoto, David J. DeGraff, Jennifer Wei Zou +8 more

PACCT: An intervention to improve communication quality and clinical trial invitations for Black and White men with prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e24137

N/A

0DataRank · unranked

0 citations

Nicole Senft, Seongho Kim, Hyejeong Jang, Mark Manning, Tanina Foster +6 more

Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)

European Urology Focus(2023)10.1016/j.euf.2023.06.006

N/A

0DataRank · unranked

49 citations

Xiangying Chu, Noah M. Hahn, Eugene J. Pietzak, Angela B. Smith, Daniel H. Shevrin +9 more

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02661

N/A

0DataRank · unranked

29 citations

Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher J. Logothetis +15 more

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5070

N/A

0DataRank · unranked

8 citations

Akash Roy, Siyuan S Guo, Larysa Rydzewska, Peter J. Godolphin, Maha Hussain +15 more

Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5087

N/A

0DataRank · unranked

4 citations

Benjamin A. Teply, Su Jin Lim, Hao Wang, Shifeng Mao, William Kevin Kelly +10 more

Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.123

N/A

0DataRank · unranked

1 citations

Yu‐Hui Chen, Christopher Sweeney, David F. Jarrard, Elizabeth R. Plimack, Benjamin A. Gartrell +7 more

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5118

N/A

0DataRank · unranked

1 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more

Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps402

N/A

0DataRank · unranked

0 citations

Yu‐Hui Chen, Steve Y. Cho, Fenghai Duan, Christos E. Kyriakopoulos, Alicia K. Morgans +10 more

Data from Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

(2023)10.1158/0008-5472.c.6513589.v1

N/A

0DataRank · unranked

0 citations

Janet Mendonca, Olutosin Owoyemi, Kavya Boyapati, Naiju Thomas, Suthicha Kanacharoen +20 more

Data from Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo

(2023)10.1158/1535-7163.c.6531786

N/A

0DataRank · unranked

0 citations

Sumit Isharwal, P. J. van Diest, Wasim H. Chowdhury, Cameron Marlow, Michael A. Carducci +3 more

Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5014

N/A

0DataRank · unranked

0 citations

Xiangying Chu, David F. Jarrard, Michael A. Carducci, Robert S. DiPaola, Lynne I. Wagner +4 more

1833P Concurrent high-dose IV Vitamin C (IVC) and docetaxel for metastatic castrate-resistant prostate cancer (mCRPC): A randomized, placebo-controlled, double-blind phase II trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.2781

N/A

0DataRank · unranked

0 citations

M.L. Zahurek, Adel Mandl, Michelle A. Rudek, Elisabeth I. Heath, Catherine H. Marshall +13 more

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.01535

N/A

0DataRank · unranked

29 citations

Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter J. Godolphin, Maha Hussain +15 more

Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer

European Urology Oncology(2024)10.1016/j.euo.2024.11.009

N/A

0DataRank · unranked

13 citations

Yi Ren, Meghan Tierney, Trevor J. Royce, Rikiya Yamashita, Danielle Croucher +13 more

Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models

The Prostate(2024)10.1002/pros.24707

N/A

0DataRank · unranked

12 citations

Adel Mandl, Timothy Krueger, Susan L. Dalrymple, Lizamma Antony, Jennifer Dias +16 more

Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED)

European Urology Oncology(2024)10.1016/j.euo.2024.04.010

N/A

0DataRank · unranked

8 citations

Xiangying Chu, David F. Jarrard, Michael A. Carducci, Robert S. DiPaola, Lynn I. Wagner +4 more

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

JU Open Plus(2024)10.1097/ju9.0000000000000137

N/A

0DataRank · unranked

7 citations

Alan H. Bryce, Maha Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R. Cooperberg +33 more

Exploring the links of skeletal muscle mitochondrial oxidative capacity, physical functionality, and mental well-being of cancer survivors

Scientific Reports(2024)10.1038/s41598-024-52570-x

N/A

0DataRank · unranked

3 citations

Leorey N. Saligan, Christopher M. Bergeron, Philip R. Lee, Kenneth W. Fishbein, Richard G. Spencer +8 more

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

JU Open Plus(2024)10.1097/ju9.0000000000000138

N/A

0DataRank · unranked

3 citations

E. David Crawford, Neeraj Agarwal, Maha Hussain, Himisha Beltran, Matthew R. Cooperberg +33 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial

European Urology Oncology(2025)10.1016/j.euo.2025.04.003

N/A

0DataRank · unranked

1 citations

Xiangying Chu, Charles J. Ryan, Arjun Gupta, Christopher J. Sweeney, David F. Jarrard +10 more

HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2019.6496

N/A

0DataRank · unranked

75 citations

Christopher J. Sweeney, Nima Almassi, Chad A. Reichard, C.A. Reddy, Hong Li +9 more

Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)

The Prostate(2020)10.1002/pros.24074

N/A

0DataRank · unranked

21 citations

Victoria X. Wang, Anis Hamid, Gabriella Santone, Charles G. Drake, Michael A. Carducci +4 more

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1412

N/A

0DataRank · unranked

8 citations

Eric Laille, Ulka N. Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati +16 more

Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.162

N/A

0DataRank · unranked

18 citations

Victoria Wang, Yu‐Hui Chen, Felix Y. Feng, Robert B. Den, Gerhardt Attard +10 more

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.116

N/A

0DataRank · unranked

2 citations

Ryan Phillips, William T. Shi, Su Jin Lim, Emmanuel S. Antonarakis, Steven P. Rowe +15 more

Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.171

N/A

0DataRank · unranked

1 citations

Victoria Wang, Hidemi S. Yamamoto, Anis Hamid, Charles G. Drake, Michael A. Carducci +4 more

RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5576

N/A

0DataRank · unranked

1 citations

Hao Wang, Michael T. Schweizer, Michael A. Carducci, Channing J. Paller, Benjamin A. Teply +5 more

End-of-life characteristics associated with short hospice length of service for patients with solid tumors enrolled on phase I clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e24005

N/A

0DataRank · unranked

0 citations

Alison E. Turnbull, Amanda L. Blackford, Arjun Gupta, Janet Heussner, Kelly Griffiths +2 more

Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

UNC Libraries(2020)10.17615/3mgt-tk63

N/A

0DataRank · unranked

0 citations

Derek Raghavan, R. Bryan Rumble, James Williams, James N. Frame, D. Andrew Loblaw +15 more

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited

European Urology(2021)10.1016/j.eururo.2020.12.040

N/A

0DataRank · unranked

100 citations

Kim Van der Eecken, Ryan Phillips, Neil R. Parikh, Pedro Isaacsson Velho, Tamara L. Lotan +19 more

Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

Cancer Research(2021)10.1158/0008-5472.can-20-3607

N/A

0DataRank · unranked

48 citations

Janet Mendonca, Olutosin Owoyemi, Kavya Boyapati, Naiju Thomas, Suthicha Kanacharoen +20 more